Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £1 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £1 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 43.8% | -36% | -2% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 41.2% | 44.4% | 49.4% | 57.9% |
| EBITDA | -£0 | -£0 | -£0 | £0 |
| % Margin | -11.1% | -166% | -7.7% | 23.3% |
| Net Income | -£0 | -£0 | -£0 | £0 |
| % Margin | -33.5% | -175.9% | -28% | 13.3% |
| EPS Diluted | -0.42 | -1.63 | -0.41 | 0.22 |
| % Growth | 74.2% | -297.6% | -286.4% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | £0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | £0 |